Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Sarcoma 4

Conditions

Lymphoma 161Leukemia 99Lymphoma, Large B-Cell, Diffuse 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 91Leukemia, Myeloid, Acute 76Hodgkin Disease 73Lymphoma, Follicular 63Burkitt Lymphoma 60Lymphoma, Mantle-Cell 56Lymphoma, Large-Cell, Immunoblastic 55Small Cell Lung Carcinoma 46Leukemia, Lymphocytic, Chronic, B-Cell 42Lung Neoplasms 41Neuroblastoma 40Lymphoma, B-Cell, Marginal Zone 33Congenital Abnormalities 33Multiple Myeloma 30Recurrence 27Sarcoma 26Central Nervous System Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Myelodysplastic Syndromes 24Leukemia, Myelomonocytic, Acute 24Leukemia, Monocytic, Acute 24Leukemia, Erythroblastic, Acute 24Testicular Neoplasms 22Lymphoma, Large-Cell, Anaplastic 22Leukemia, Megakaryoblastic, Acute 22Brain Neoplasms 22

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 21Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Glioma × Etoposide × Clear all
NCT00303849 2022-03-17

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

OHSU Knight Cancer Institute

Phase 1/2 Completed
33 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

NCT00047281 2017-07-11

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Dana-Farber Cancer Institute

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00612430 2013-08-12

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

Duke University

Phase 2 Completed
59 enrolled 10 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00613223 2013-02-20

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Duke University

Phase 1 Completed
49 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡